

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**November 30, 2015  
Date of Report (Date of Earliest Event Reported)**

---

**The Chemours Company**  
(Exact Name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
Of Incorporation)

**001-36794**  
(Commission  
File Number)

**46-4845564**  
(I.R.S. Employer  
Identification No.)

**1007 Market Street  
Wilmington, Delaware, 19899**  
(Address of principal executive offices)

**Registrant's telephone number, including area code: (302) 773-1000**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 7.01 Regulation FD Disclosure.**

As previously announced, senior management of The Chemours Company (the "Company") will be presenting at the Citi Basic Materials Conference in New York City on December 1, 2015 at 9:30 a.m. and a live webcast will be available via the Investor Relations section of the Company's website. The presentation slides for the conference are furnished herewith as Exhibit 99.1 and will also be available on the Company's website.

The Citi Presentation Slides are being furnished pursuant to Item 7.01, and the information contained therein shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Furthermore, the information contained in Exhibit 99.1 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Citi Presentation Slides dated December 1, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE CHEMOURS COMPANY

**By:** /s/ Mark E. Newman  
Mark E. Newman  
Senior Vice President and  
Chief Financial Officer

Date: November 30, 2015

# The Chemours Company

## Investor Presentation

December 2015

## Safe Harbor Statement

This presentation contains forward-looking statements, which often may be identified by their use of words like “plans,” “expects,” “will,” “believes,” “intends,” “estimates,” “anticipates” or other words of similar meaning. These forward-looking statements address, among other things, our anticipated future operating and financial performance, business plans and prospects, transformation plans, resolution of environmental liabilities, litigation and other contingencies, plans to increase profitability, our ability to pay or the amount of any dividend, and target leverage that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements as further described in the “Risk Factors” section of the information statement contained in the registration statement on Form 10 and other filings made by Chemours with the Securities and Exchange Commission. Chemours undertakes no duty to update any forward-looking statements.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA, which should not be considered as replacements of GAAP. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS and Adjusted EBITDA to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Historical results prior to July 1, 2015 are presented on a stand-alone basis from DuPont historical results and are subject to certain adjustments and assumptions as indicated in this presentation, and may not be an indicator of future performance.

Additional information for investors is available on the company’s website at [investors.chemours.com](http://investors.chemours.com).



# The Chemours Company at a Glance




LTM Sales: \$5,906  
 LTM Adj. EBITDA: \$646  
 % margin: 11%

Titanium Technologies	
Sales:	\$2,491
Adj. EBITDA:	422
% margin:	17%
<ul style="list-style-type: none"> <li>Titanium dioxide (TiO<sub>2</sub>) is a pigment used to deliver whiteness, opacity, brightness and protection from sunlight</li> <li><b>#1 global producer of TiO<sub>2</sub> by capacity, sales and profitability</b></li> </ul>	


Fluoroproducts	
Sales:	\$2,290
Adj. EBITDA:	291
% margin:	13%
<ul style="list-style-type: none"> <li>Products for high performance applications across broad array of industries, including refrigerants, propellants and industrial resins</li> <li><b>#1 global producer of both fluorochemicals and fluoropolymers</b></li> </ul>	

Chemical Solutions	
Sales:	\$1,125
Adj. EBITDA:	13
% margin:	1%
<ul style="list-style-type: none"> <li>Chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries</li> <li><b>#1 producer in Americas sodium cyanide</b></li> <li><b>#1 in US Northeast sulfuric acid regeneration</b></li> <li><b>#2 in US Gulf Coast sulfuric acid regeneration</b></li> </ul>	

By Geography



By Product




Dollars in millions. Data represents twelve months ending September 30, 2015. Adjusted EBITDA includes corporate and other charges which are not reflected in individual segment Adjusted EBITDA. Geographic and product data reflect full year 2014 sales. See reconciliation of Adjusted EBITDA in Appendix.

# Titanium Technologies Business Overview


## Business Overview

- Global leader in TiO<sub>2</sub> with production capacity of 1.2 million metric tons<sup>(1)</sup>
  - 4 TiO<sub>2</sub> plants with 7 production lines<sup>(1)</sup>
  - Packaging facility at Kallo, Belgium
  - Mineral sands mine at Starke, FL
- Industry-leading manufacturing cost position
  - Unique chloride technology
  - Feedstock flexibility
- Strong brand reputation
  - Ti-Pure® sold to ~850 customers globally


## Chemours is #1 in TiO<sub>2</sub> Globally<sup>(2)</sup>



## Geography<sup>(4)</sup>



## End Market<sup>(4)</sup>



- **Coatings** – architectural, industrial, automotive
- **Plastics** – rigid / flexible packaging, PVC pipe/windows
- **Papers** – laminate papers, coated paper/paperboard, sheet
- **Specialty** – rubber, leather, diesel particulate filters

Source: Company filings and data. Titanium Technologies: TZMI (2014)

(1) Pro forma for completion of Altamira expansion in mid-2016

(2) TiO<sub>2</sub> market share statistics based on production per TZMI

(3) Pro forma for Rockwood acquisition (Sachtleben)

(4) Reflects full year 2014 segment net sales




# Fluoroproducts Business Overview


## Business Overview

- Supplies products for high performance applications across broad array of industries
- #1 in Fluoroproducts globally
  - Fluorochemicals: #1 in refrigerants, #1 in propellants, #3 in foaming agents
  - Fluoropolymers: #1 in industrial resins, #1 in fluoropolymer specialties
- Key Brands include Teflon®, Freon®, Opteon®, Viton®


## Chemours is #1 in Fluoroproducts Globally<sup>(2)</sup>



Geography<sup>(1)</sup>



Product<sup>(1)</sup>



- **Fluorochemicals** – mainly refrigerants, propellants, and foam expansion agent
- **Fluoropolymers** – mainly industrial resins and downstream products & coatings
- **Key End Markets** – AC, refrigeration, automotive, aerospace, consumer, wire & cable, electronics and telecommunications

Source: Company filings and data, Fluoroproducts: Company filings and Management estimates

(1) Reflects full year 2014 segment net sales

(2) Fluorochemicals and fluoropolymers market share statistics based on internal revenue estimates and company filings

(3) Includes 100% contribution from the DuPont-Mitsui Fluorocarbon Company joint venture







# Chemical Solutions Overview

## Business Overview

- Diverse portfolio of industrial businesses primarily operating in the Americas
- Unmatched reputation for safety, reliability and stewardship
- 14 production facilities located in North America and one located in the U.K.

## Cyanide Competitive Advantages

- Market leadership
- Favorable end market dynamics
- Selective, high-return investment opportunity



- **Cyanides** – sodium cyanide, hydrogen cyanide, potassium cyanide
- **Sulfur Products** – non-fuming sulfuric acid, spent acid regeneration, sulfur derivatives
- **Performance Chemicals and Intermediates** – aniline, methylamines, reactive metals, clean and disinfect chemicals

Source: Company filings and data  
(1) Reflects full year 2014 segment net sales



# Chemours Transformation Plan

# Transformation Plan Priorities

## Reduce Costs

- Target cost reductions of ~\$100M in second half of 2015
- Target additional cost reduction of \$350M through 2017 over 2015

## Optimize The Portfolio

- Retaining and investing in Cyanides business
- Signed definitive agreement to sell Aniline facility
- Retaining and strengthening Methylamines business
- Evaluating strategic alternatives for all other assets in the Chemical Solutions portfolio

## Grow Market Positions

- Support customer growth in TiO<sub>2</sub> through successful Altamira start-up
- Continue ramp up of Opteon™ product line in Fluoroproducts
- Grow Cyanides business within Chemical Solutions
- Target \$150M Adjusted EBITDA growth from Altamira, Opteon™ and Cyanides through 2017

## Refocus Investments

- Concentrate capital spending on investable business portfolio
- Invest in the next increment of Opteon™ and Cyanides capacity
- Rationalize annual capital spending to ~\$350M in 2017

## Enhance Our Organization

- Foster an entrepreneurial organization
- Operate with a simpler structure
- Maintain a commitment to a safe and sustainable future


Enhance Adjusted EBITDA by \$500M and Improve Leverage Position to ~3x in 2017



\$M represents millions, \$B represents billions


# Transformation Plan Priorities: Reduce Costs

## Cost Reduction Activities Targeting ~\$450 Million in Cumulative Savings




# Transformation Plan Priorities: Optimize The Portfolio

## Progress on Strategic Review of Chemical Solutions



## Opteon™ Technology Adoption Accelerating



### Market-Leading Portfolio of Low GWP Products



**Opteon™ YF**  
Next Gen Gas for MAC



**Opteon™ YF blends**  
Next Gen Gas for Commercial Refrigeration, Residential/Light Commercial A/C, Chillers, High Temp Heat Pump



**HFO-1336(Z)**  
Next Gen Liquids for Foams, Centrifugal Chillers, Organic Rankine Cycles, High Temp Heat Pumps

### Altamira & Cyanides Expansions – On Track

#### Altamira Expansion

- 200,000 metric ton capacity, one of the lowest cost production lines
- Production scheduled to start up in mid-2016
- Adds low-cost capacity and provides incremental fixed cost leverage
- Expected to deliver ~\$20 – \$70 million net EBITDA cost benefit, depending on ore price

#### Cyanides Expansion

- 50% increase in capacity
- Helps meet growing demand in North American gold production
- Utilizes proprietary technology to deliver low-cost product
- Maintains excellent stewardship standards

Altamira and Cyanides Initiatives Expected to Deliver ~\$50M of Adjusted EBITDA Growth through 2017

## Transformation Plan Priorities: Refocus Investments and Enhance Financial Position

### Path Toward Improving Free Cash Flow

#### Sources of Cash

- \$500M Adjusted EBITDA improvement
- \$140M gross sale proceeds from Aniline
- Chemical Solutions strategic review could yield additional proceeds in 2016
- Working capital
  - Second half seasonal unwind
  - Permanent reduction of cash usage
- ~\$100M reduction in capital expenditures

#### Uses of Cash

- Capital expenditures ~\$350M in 2017
  - Altamira start-up by mid-2016
  - Cyanides expansion expected to be completed by mid-2017
- One time restructuring costs

Free Cash Flow Generation Expected to Accelerate in 2017





# Chemours Transformation Plan Results

Global Market Leader with Premier Cost Position

- Global leader in titanium dioxide and fluoroproducts
- Proprietary products and brands with above-average growth
- Low cost assets provide advantaged position across the cycle



Transformation Plan  
Multiple Organic Growth Opportunities

- Titanium Technologies – Altamira expansion
- Fluoroproducts – Opteon™ adoption
- Chemical Solutions – Cyanides expansion



Transformation Plan  
Lower Costs and Capex across Optimized Portfolio

- Streamline cost structure
- Portfolio optimization
- Reduce working capital
- Lower capital expenditure



Enhance Adjusted EBITDA by \$500M and Improve Leverage Position to ~3x in 2017





**Chemours™**

©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company

# Appendix

## Reconciliation of Adjusted EBITDA to Net (Loss) Income

	Three Months Ended		Nine Months Ended		Last Twelve Months
	September 30,		September 30,		September 30,
<i>(\$ in millions)</i>	2015	2014	2015	2014	2015
Total Adjusted EBITDA	\$169	\$235	\$441	\$671	\$646
Interest	(51)	-	(79)	-	(79)
Depreciation and amortization	(70)	(57)	(201)	(185)	(273)
Non-operating pension and other postretirement employee benefit costs	10	(3)	(5)	(18)	(9)
Exchange gains (losses)	44	(33)	47	(29)	10
Asset impairments	(70)	-	(70)	-	(70)
Restructuring charges	(139)	-	(200)	(21)	(200)
Gains (losses) on sale of business or assets	-	1	-	12	28
(Loss) income before income taxes	(107)	143	(67)	430	53
(Benefit from) provision for income taxes	(78)	35	(63)	108	(22)
Net (loss) income	\$(29)	\$108	\$(4)	\$322	\$75

# Segment Net Sales and Adjusted EBITDA

## SEGMENT NET SALES (UNAUDITED)

(dollars in millions)

SEGMENT NET SALES	LTM				
	2015	3Q15	2Q15	1Q15	4Q14
Titanium Technologies	2,491	616	642	545	688
Fluoroproducts	2,290	575	588	552	575
Chemical Solutions	1,125	295	278	266	286
<b>TOTAL NET SALES</b>	<b>5,906</b>	<b>1,486</b>	<b>1,508</b>	<b>1,363</b>	<b>1,549</b>

## ADJUSTED EBITDA BY SEGMENT (UNAUDITED)

(dollars in millions)

SEGMENT ADJUSTED EBITDA	LTM				
	2015	3Q15	2Q15	1Q15	4Q14
Titanium Technologies	422	78	91	93	160
Fluoroproducts	291	89	54	75	73
Chemical Solutions	13	7	4	1	1
Corporate & Other	(80)	(5)	(22)	(24)	(29)
<b>TOTAL ADJUSTED EBITDA</b>	<b>646</b>	<b>169</b>	<b>127</b>	<b>145</b>	<b>205</b>

Note: In September 2015, the definition of Adjusted EBITDA was updated. All prior periods have been updated to reflect the current presentation.





**Chemours™**

©2015 The Chemours Company. Chemours™ and the Chemours Logo are trademarks or registered trademarks of The Chemours Company